# Sermorelin References: The Cited Literature Record | Sermorelin

> The full sermorelin reference list — every PubMed citation, DOI, and PMID behind the GH/IGF-1, pharmacokinetic, and regenerative-frontier claims on this site.

The complete source register. Every quantitative claim across this site resolves to a numbered record below, with DOI and PubMed identifiers exposed.

## The cited record

Every numbered citation used across this site is logged below with its journal, year, DOI, and PubMed identifier. The list mixes confirmed human and pharmacokinetic records with the angle and supporting tiers (the regenerative, cardiac, and in-silico oncology signals); the tier of each finding is stated where it is cited in the body. This is [sermorelin references and citations](/references) as a flat source register — the machine-readable substrate beneath the prose.

## References

[1] Granata R, Leone S, Zhang X, Gesmundo I, Steenblock C, Cai R, Sha W, Ghigo E, Hare JM, Bornstein SR, Schally AV. Growth hormone-releasing hormone and its analogues in health and disease. Nat Rev Endocrinol. 2025. https://pubmed.ncbi.nlm.nih.gov/39537825/
[2] Blackman MR. Use of growth hormone secretagogues to prevent or treat the effects of aging: not yet ready for prime time. Ann Intern Med. 2008;149(9):677-9. https://pubmed.ncbi.nlm.nih.gov/18981489/
[3] Wilton P, Chardet Y, Danielson K, Widlund L, Gunnarsson R. Pharmacokinetics of growth hormone-releasing hormone(1-29)-NH2 and stimulation of growth hormone secretion in healthy subjects after intravenous or intranasal administration. Acta Paediatr Suppl. 1993;388:10-15. https://pubmed.ncbi.nlm.nih.gov/8329825/
[4] Thorner M, Rochiccioli P, Colle M, Lanes R, Grunt J, Galazka A, Landy H, Eengrand P, Shah S. Once daily subcutaneous growth hormone-releasing hormone therapy accelerates growth in growth hormone-deficient children during the first year of therapy. J Clin Endocrinol Metab. 1996;81(3):1189-96. https://pubmed.ncbi.nlm.nih.gov/8772599/
[5] Corpas E, Harman SM, Pineyro MA, Roberson R, Blackman MR. Growth hormone (GH)-releasing hormone-(1-29) twice daily reverses the decreased GH and insulin-like growth factor-I levels in old men. J Clin Endocrinol Metab. 1992;75(2):530-535. https://pubmed.ncbi.nlm.nih.gov/1379256/
[6] Cui T, Jimenez JJ, Block NL, et al. Agonistic analogs of growth hormone releasing hormone (GHRH) promote wound healing by stimulating the proliferation and survival of human dermal fibroblasts through ERK and AKT pathways. Oncotarget. 2016;7(33):52661-52672. https://pubmed.ncbi.nlm.nih.gov/27494841/
[7] Bagno L, et al. New therapeutic approach to heart failure due to myocardial infarction based on targeting growth hormone-releasing hormone receptor. Oncotarget. 2015;6(13):10846-10859. https://pubmed.ncbi.nlm.nih.gov/25797248/
[8] Chang Y, Huang R, Zhai Y, et al. A potentially effective drug for patients with recurrent glioma: sermorelin. Ann Transl Med. 2021;9(5):406. https://pubmed.ncbi.nlm.nih.gov/33842627/
[9] Schally AV, Cai R, et al. The development of growth hormone-releasing hormone analogs: Therapeutic advances in cancer, regenerative medicine, and metabolic disorders. Rev Endocr Metab Disord. 2025. https://pubmed.ncbi.nlm.nih.gov/39592529/
[10] Walker RF. Sermorelin: a better approach to management of adult-onset growth hormone insufficiency? Clin Interv Aging. 2006;1(4):307-308. https://pubmed.ncbi.nlm.nih.gov/18046908/
[11] Baker LD, Barsness SM, Borson S, Merriam GR, Friedman SD, Craft S, Vitiello MV. Effects of growth hormone-releasing hormone on cognitive function in adults with mild cognitive impairment and healthy older adults: results of a controlled trial. Arch Neurol. 2012;69(11):1420-1429. https://pubmed.ncbi.nlm.nih.gov/22869065/
[12] Stanley TL, Chen CY, Branch KL, et al. Effects of a growth hormone-releasing hormone analog on endogenous GH pulsatility and insulin sensitivity in healthy men. J Clin Endocrinol Metab. 2011;96(1):150-158. https://pubmed.ncbi.nlm.nih.gov/20943777/
[13] Vance ML, Evans WS, Kaiser DL, et al. The effect of intravenous, subcutaneous, and intranasal GH-RH analog, [Nle27]GHRH(1-29)-NH2, on growth hormone secretion in normal men: dose-response relationships. Clin Pharmacol Ther. 1986;40:627-33. https://pubmed.ncbi.nlm.nih.gov/3096623/

---

A near-black terminal record of the sermorelin literature — GHRH(1-29) traced from receptor to IGF-1, each datum logged to its source and tagged by tier, with the confirmed human data kept apart from the regenerative and in-silico frontier signals; no clinic behind the console and nothing here dispensed or sold.